Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022977 | 0.81 | TDP1 (0.33) | KDM4EALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL3005779 | 0.78 | KDM4E (0.35) | KDM4E | |
| SCHEMBL5513040 | 0.69 | CA2 (0.41) | KDM4EALDH1A1MAPTHPGDPOLB | |
| SCHEMBL4996644 | 0.68 | CFTR (0.37) | KDM4EALDH1A1MAPTHPGDATM | |
| SCHEMBL3200825 | 0.65 | HTT (0.42) | KDM4EALDH1A1MAPTHPGDPRKCE | |
| SCHEMBL27403233 | 0.65 | RIPK1 (0.40) | POLBL3MBTL1PRKCERET | |
| SCHEMBL5006585 | 0.63 | KDM4E (0.40) | KDM4EALDH1A1MAPTHPGDATM | |
| SCHEMBL28808723 | 0.63 | ALDH1A1 (0.39) | KDM4EALDH1A1POLBL3MBTL1PRKCE | |
| SCHEMBL2118434 | 0.61 | NPC1 (0.33) | KDM4E | |
| SCHEMBL3016189 | 0.59 | TDP1 (0.35) | ALDH1A1MAPTHPGDATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | CDK8 3371/4885CDK19 3860/4885KDM4E 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.